• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Verification of systemic response and tumor microenvironment change in triple-negative breast cancer based on immune response

Research Project

Project/Area Number 20K08938
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 55010:General surgery and pediatric surgery-related
Research InstitutionOsaka Metropolitan University (2022-2023)
Osaka City University (2020-2021)

Principal Investigator

Kashiwagi Shinichiro  大阪公立大学, 大学院医学研究科, 教授 (80637017)

Co-Investigator(Kenkyū-buntansha) 浅野 有香  大阪公立大学, 大学院医学研究科, 病院講師 (10806376)
藤田 寿一  大阪公立大学, 大学院看護学研究科, 准教授 (30212187)
Project Period (FY) 2020-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2022: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2021: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2020: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords乳癌 / 腫瘍微小環境 / 腫瘍免疫 / トリプルネガティブ乳癌 / 免疫療法 / 腫瘍免疫応答
Outline of Research at the Start

腫瘍組織は,癌細胞とその周囲に存在する間質細胞から構成され,相互作用により腫瘍微小環境と称される特徴的な環境を形成している.そして癌治療において,宿主の腫瘍微小環境の評価が,予後や治療効果を予測する上で重要な役割を担う.近年,乳癌領域においても免疫療法の有用性が報告されている.免疫療法は,とくに免疫原性が高いとされるトリプルネガティブ乳癌における有用性が示されている.本研究では,宿主の全身反応や腫瘍免疫微小環境の変化をダイナミックに捉え,その動態変化や免疫フェノタイプの理解により従来の薬物療法と免疫療法との併用療法や逐次療法など,免疫療法を柱とする次世代の乳癌薬物個別化療法の構築を目指す.

Outline of Final Research Achievements

Tumor tissues present a characteristic environment called the tumor microenvironment (TME) due to interactions between cancer cells and surrounding stromal cells. Since evaluation of the TME in the host is related to predicting therapeutic effects and prognosis, monitoring the TME is a key factor in cancer treatment.
In this study, titled "Verification of systemic reactions and microenvironmental changes in triple-negative breast cancer as seen from immune responses," we examined next-generation personalized breast cancer drug therapy centered on immunotherapy. It was suggested that immunotherapy may enhance tumor immunity by using anticancer drugs in combination.

Academic Significance and Societal Importance of the Research Achievements

腫瘍微小環境は薬剤修飾によりダイナミックな変化を示すために,この動的な変化をモニタリングすることでトリプルネガティブ乳癌の新たな治療戦略の構築に寄与する可能性が示された.

Report

(5 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • 2020 Research-status Report
  • Research Products

    (13 results)

All 2023 2022 2020

All Journal Article (13 results) (of which Int'l Joint Research: 6 results,  Peer Reviewed: 13 results,  Open Access: 13 results)

  • [Journal Article] Eribulin treatment promotes re-expression of estrogen receptor in endocrine therapy-resistant hormone receptor-positive breast cancer cells.2023

    • Author(s)
      Goto W, Kashiwagi S, Iimori N, Kouhashi R, Yabumoto A, Takada K, Asano Y, Tauchi Y, Ogisawa K, Morisaki T, Shibutani M, Tanaka H, Maeda K.
    • Journal Title

      Anticancer Research

      Volume: 43 Issue: 2 Pages: 603-611

    • DOI

      10.21873/anticanres.16196

    • Related Report
      2023 Annual Research Report 2022 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Clinical verification on the relationship between serum lipid metabolism and the immune activity in breast cancer patients treated with neoadjuvant chemotherapy.2023

    • Author(s)
      Goto W, Kashiwagi S, Takada K, Asano Y, Ogisawa K, Morisaki T, Shibutani M, Tanaka H, Maeda K.
    • Journal Title

      European Journal of Medical Research

      Volume: 28 Issue: 1 Pages: 2-2

    • DOI

      10.1186/s40001-022-00964-w

    • Related Report
      2023 Annual Research Report 2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Clinical verification of the predictors for febrile neutropenia in breast cancer patients treated with neoadjuvant chemotherapy.2023

    • Author(s)
      Goto W, Kashiwagi S, Matsuoka K, Iimori N, Kouhashi R, Yabumoto A, Takada K, Asano Y, Tauchi Y, Ogisawa K, Morisaki T, Shibutani M, Tanaka H, Maeda K.
    • Journal Title

      Anticancer Research

      Volume: 43 Issue: 1 Pages: 247-251

    • DOI

      10.21873/anticanres.16156

    • Related Report
      2023 Annual Research Report 2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer.2023

    • Author(s)
      Takada K, Kashiwagi S, Iimori N, Yabumoto A, Goto W, Asano Y, Tauchi Y, Morisaki T, Ogisawa K, Shibutani M, Tanaka H, Maeda K.
    • Journal Title

      BMC Cancer

      Volume: 23 Issue: 1 Pages: 224-224

    • DOI

      10.1186/s12885-023-10631-w

    • Related Report
      2023 Annual Research Report 2022 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Factor analysis of intraoperative bleeding loss and its impact on prognosis in breast cancer2023

    • Author(s)
      Takada K, Kashiwagi S, Iimori N, Kouhashi R, Yabumoto A, Goto W, Asano Y, Tauchi Y, Ogisawa K, Morisaki T, Shibutani M, Tanaka H, Maeda K.
    • Journal Title

      Anticancer Research

      Volume: 43 Issue: 1 Pages: 191-200

    • DOI

      10.21873/anticanres.16149

    • Related Report
      2023 Annual Research Report 2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Outcome prediction after neoadjuvant chemotherapy (NAC) for breast cancer, using tumor-infiltrating lymphocytes within fibrotic foci of tumor stroma (FF-TILs).2022

    • Author(s)
      Kashiwagi S, Asano Y, Takada K, Goto W, Morisaki T, Shibutani M, Tanaka H, Hirakawa K, Ohira M.
    • Journal Title

      Anticancer Research

      Volume: 42 Issue: 3 Pages: 1421-1431

    • DOI

      10.21873/anticanres.15612

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Clinical significance of expression of immunoadjuvant molecules (LAG-3, TIM-3, OX-40) in neoadjuvant chemotherapy for breast cancer.2022

    • Author(s)
      Asano Y, Kashiwagi S* Takada K, Ishihara S, Goto W, Morisaki T, Shibutani M, Tanaka H, Hirakawa K, Ohira M.
    • Journal Title

      Anticancer Research

      Volume: 42 Issue: 1 Pages: 125-136

    • DOI

      10.21873/anticanres.15466

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Validation of systemic and local tumour immune response to eribulin chemotherapy to treat breast cancer.2020

    • Author(s)
      Kashiwagi S, Asano Y, Goto W, Takada K, Morisaki T, Kouhashi R, Yabumoto A, Tanaka S, Takashima T, Ohsawa M, Hirakawa K, Ohira M.
    • Journal Title

      Anticancer Research

      Volume: 40 Issue: 6 Pages: 3345-3354

    • DOI

      10.21873/anticanres.14317

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Predicting therapeutic efficacy of endocrine therapy for stage IV breast cancer by tumor infiltrating lymphocytes2020

    • Author(s)
      Asano Yuka、Kashiwagi Shinichiro、Goto Wataru、Takada Koji、Takahashi Katsuyuki、Shibutani Masatsune、Amano Ryosuke、Takashima Tsutomu、Tomita Shuhei、Hirakawa Kosei、Ohira Masaichi
    • Journal Title

      Molecular and Clinical Oncology

      Volume: 13 Issue: 2 Pages: 195-202

    • DOI

      10.3892/mco.2020.2063

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment2020

    • Author(s)
      Goto Wataru、Kashiwagi Shinichiro、Asano Yuka、Takada Koji、Morisaki Tamami、Takahashi Katsuyuki、Fujita Hisakazu、Shibutani Masatsune、Amano Ryosuke、Takashima Tsutomu、Tomita Shuhei、Hirakawa Kosei、Ohira Masaichi
    • Journal Title

      BMC Cancer

      Volume: 20 Issue: 1 Pages: 1215-1215

    • DOI

      10.1186/s12885-020-07673-9

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] The effect of smoking on biological change of recurrent breast cancer.2020

    • Author(s)
      Takada K, Kashiwagi S, Asano Y, Goto W, Kouhashi R, Yabumoto A, Morisaki T, Fujita H, Shibutani M, Takashima T, Hirakawa K, Ohira M.
    • Journal Title

      Journal of Translational Medicine

      Volume: 18 Issue: 1 Pages: 153-153

    • DOI

      10.1186/s12967-020-02307-x

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ2020

    • Author(s)
      Takada Koji、Kashiwagi Shinichiro、Asano Yuka、Goto Wataru、Morisaki Tamami、Takahashi Katsuyuki、Fujita Hisakazu、Takashima Tsutomu、Tomita Shuhei、Hirakawa Kosei、Ohira Masaichi
    • Journal Title

      BMC Cancer

      Volume: 20 Issue: 1 Pages: 513-513

    • DOI

      10.1186/s12885-020-07001-1

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Prediction of lymph node metastasis by tumor-infiltrating lymphocytes (TILs) in T1 breast cancer.2020

    • Author(s)
      Takada K, Kashiwagi S, Asano Y, Goto W, Kouhashi R, Yabumoto A, Morisaki T, Shibutani M, Takashima T, Fujita H, Hirakawa K, Ohira M.
    • Journal Title

      BMC Cancer

      Volume: 20 Issue: 1 Pages: 598-598

    • DOI

      10.1186/s12885-020-07101-y

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research

URL: 

Published: 2020-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi